RVTY Revvity
Solid consumables franchise, but $159 assumes margins and growth well above what post-COVID tools economics support.
The story
Revvity is a life sciences tools and diagnostics company (reagents, immunodiagnostics, newborn screening, software) that emerged from PerkinElmer's breakup. Its moat comes from recurring consumables and razor/blade installed bases, and BioLegend reagents and newborn screening give it real niche franchises. After the COVID revenue cliff it is now a mature, mid-single-digit grower. Reported margins are depressed by roughly $280M a year of acquisition amortization, which hides underlying cash economics in the mid-20s.
The 0.28 trailing sales-to-capital and 11% GAAP margin reflect goodwill and amortization from past deals, not incremental economics. I use a 26% target margin, which approximates pre-amortization peer-level tools economics short of the ~28% adjusted peak, and 1.5 incremental sales-to-capital for a consumables-heavy model. Growth of 5-6% reflects post-COVID normalization with a recovery in biopharma and China spending, and the 10-year horizon credits the recurring-revenue franchise without treating it as a wide-moat compounder.
Value drivers
| Revenue growth (Y1) | 5.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 10y |
| Target operating margin | 26.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.50 |
| Beta | 0.95 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.3% |
| Terminal WACC | 9.5% |
Valuation bridge
| PV of explicit FCFF | 4.00B |
| PV of terminal value | 4.49B |
| Equity value | 6.06B |
| ÷ shares → per share | $54.28 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 3.06B | 5.0% | 14.2% | 387.40M | 97.06M | 290.34M | 265.68M |
| 2 | 3.20B | 4.8% | 17.1% | 490.62M | 97.38M | 393.24M | 329.28M |
| 3 | 3.35B | 4.6% | 20.1% | 601.54M | 97.29M | 504.25M | 386.38M |
| 4 | 3.49B | 4.3% | 23.0% | 720.01M | 96.76M | 623.25M | 437.01M |
| 5 | 3.64B | 4.1% | 26.0% | 845.82M | 95.78M | 750.04M | 481.25M |
| 6 | 3.78B | 3.9% | 26.0% | 878.71M | 94.32M | 784.39M | 460.55M |
| 7 | 3.92B | 3.7% | 26.0% | 910.93M | 92.39M | 818.54M | 439.78M |
| 8 | 4.05B | 3.4% | 26.0% | 942.31M | 89.98M | 852.33M | 419.05M |
| 9 | 4.18B | 3.2% | 26.0% | 972.67M | 87.07M | 885.60M | 398.43M |
| 10 | 4.31B | 3.0% | 26.0% | 1.00B | 83.68M | 918.18M | 378.00M |
Key risks
- China diagnostics volume-based procurement and reimbursement cuts compress the immunodiagnostics business
- NIH and academic funding cuts plus a weak biotech funding environment stall life sciences reagent demand
- Leverage (2.3B net debt) and buyback-funded EPS growth mask organic stagnation; another large acquisition at a high multiple destroys value
Catalysts
- Biopharma and academic tools demand recovers and lifts organic growth back to 6%+
- Margin expansion toward 28%+ adjusted operating margin from cost actions and software (Signals) mix